Draghia-Akli, R. et al. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat Biotechnol 17, 1179-1183, doi:10.1038/70718 (1999)
Khan, A. S. et al. Maternal GHRH plasmid administration changes pituitary cell lineage and improves progeny growth of pigs. Am J Physiol Endocrinol Metab 285, E224-231, doi:10.1152/ajpendo.00050.2003 (2003).
Draghia-Akli, R. & Fiorotto, M. L. A new plasmid-mediated approach to supplement somatotropin production in pigs. J Anim Sci 82 E-Suppl, E264-269 (2004).
Draghia-Akli, R., Ellis, K. M., Hill, L. A., Malone, P. B. & Fiorotto, M. L. High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASEB J 17, 526-528, doi:10.1096/fj.02-0671fje (2003)
Khan, A. S. et al. Optimization of electroporation parameters for the intramuscular delivery of plasmids in pigs. DNA Cell Biol 22, 807-814, doi:10.1089/104454903322625019 (2003).
Hebel, H., Attra, H., Khan, A. & Draghia-Akli, R. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine 24, 4607-4614, doi:10.1016/j.vaccine.2005.08.049 (2006).
Khan, A. S., Pope, M. A. & Draghia-Akli, R. Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol 24, 810-818, doi:10.1089/dna.2005.24.810 (2005).
Draghia-Akli R, Khan AS, Pope MA, Brown PA. 2005 Innovative electroporation for therapeutic and vaccination applications [review]. Gene Therapy and Molecular Biology. 9: 329-338.
Draghia-Akli, R., Pope, M. A., Brown, P. A. & Khan, A. S. Plasmid-based expression technology using growth hormone releasing hormone: a novel method for physiologically stimulating long-term growth hormone secretion. Comb Chem High Throughput Screen 9, 181-185 (2006).
Thacker, E. L., Holtkamp, D. J., Khan, A. S., Brown, P. A. & Draghia-Akli, R. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J Anim Sci 84, 733-742 (2006)
Brown, P. A., Khan, A. S. & Draghia-Akli, R. Delivery of DNA into skeletal muscle in large animals. Methods Mol Biol 423, 215-224, doi:10.1007/978-1-59745-194-9_15 (2008).
Hirao, L. A. et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26, 440-448, doi:10.1016/j.vaccine.2007.10.041 (2008).
Draghia-Akli, R. et al. Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine 26, 5230-5237, doi:10.1016/j.vaccine.2008.03.071 (2008).
Person, R. et al. Growth hormone-releasing hormone plasmid treatment by electroporation decreases offspring mortality over three pregnancies. Mol Ther 16, 1891-1897, doi:10.1038/mt.2008.178 (2008).
Draghia-Akli R, Smith LC. 2003 Electrokinetic Enhancement of Plasmid Delivery In Vivo. In: Templeton NS, Lasic DD (eds) Gene Therapy -- Therapeutic Mechanisms and Strategies. Marcel Dekker, Inc., New York, 245-263
Others
Khan, A. S., Brown, P. A. & Draghia-Akli, R. Plasmid-based growth hormone-releasing hormone supplementation and its applications. Curr Opin Mol Ther 7, 306-316 (2005).
Draghia-Akli, R., Hahn, K. A., King, G. K., Cummings, K. K. & Carpenter, R. H. Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol Ther 6, 830-836 (2002).
Draghia-Akli, R., Cummings, K. K., Khan, A. S., Brown, P. A. & Carpenter, R. H. Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs. J Anim Sci 81, 2301-2310 (2003)
Tone, C. M., Cardoza, D. M., Carpenter, R. H. & Draghia-Akli, R. Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs. Cancer Gene Ther 11, 389-396, doi:10.1038/sj.cgt.7700717 (2004).
Bodles-Brakhop, A. M., Brown, P. A., Pope, M. A. & Draghia-Akli, R. Double-blinded, Placebo-controlled plasmid GHRH trial for cancer-associated anemia in dogs. Mol Ther 16, 862-870, doi:10.1038/mt.2008.31 (2008)
Brown, P. A., Bodles-Brakhop, A. M., Pope, M. A. & Draghia-Akli, R. Gene therapy by electroporation for the treatment of chronic renal failure in companion animals. BMC Biotechnol 9, 4, doi:10.1186/1472-6750-9-4 (2009)
Brown, P. A., Davis, W. C. & Draghia-Akli, R. Immune-enhancing effects of growth hormone-releasing hormone delivered by plasmid injection and electroporation. Mol Ther 10, 644-651, doi:10.1016/j.ymthe.2004.06.1015 (2004).
Brown, P. A., Bodles-Brakhop, A. M. & Draghia-Akli, R. Effects of plasmid growth hormone-releasing hormone treatment during heat stress. DNA Cell Biol 27, 629-635, doi:10.1089/dna.2008.0758 (2008).
Brown, P. A., Bodles-Brakhop, A. & Draghia-Akli, R. Plasmid growth hormone releasing hormone therapy in healthy and laminitis-afflicted horses-evaluation and pilot study. J Gene Med 10, 564-574, doi:10.1002/jgm.1170 (2008).
Levy, D. N., Fernandes, L. S., Williams, W. V. & Weiner, D. B. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72, 541-550 (1993).
Ayyavoo, V. et al. HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol 62, 93-99 (1997).
Levy, D. N., Refaeli, Y., MacGregor, R. R. & Weiner, D. B. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 91, 10873-10877 (1994).
Levy, D. N., Refaeli, Y. & Weiner, D. B. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 69, 1243-1252 (1995).
Refaeli, Y., Levy, D. N. & Weiner, D. B. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci U S A 92, 3621-3625 (1995).
Stewart, S. A., Poon, B., Jowett, J. B. & Chen, I. S. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 71, 5579-5592 (1997).
Stewart, S. A., Poon, B., Jowett, J. B., Xie, Y. & Chen, I. S. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci U S A 96, 12039-12043 (1999).
Stewart, S. A., Poon, B., Song, J. Y. & Chen, I. S. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 74, 3105-3111 (2000).
Jowett, J. B. et al. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol 69, 6304-6313 (1995).
Henklein, P. et al. Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J Biol Chem 275, 32016-32026, doi:10.1074/jbc.M004044200 (2000).
Sherman, M. P., de Noronha, C. M., Pearce, D. & Greene, W. C. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol 74, 8159-8165 (2000).
He, J. et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69, 6705-6711 (1995)
Yao, X. J. et al. Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J Virol 72, 4686-4693 (1998).
Macreadie, I. G. et al. A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. Proc Natl Acad Sci U S A 92, 2770-2774 (1995).
Fletcher, T. M., 3rd et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 15, 6155-6165 (1996).
Tokushige, K. et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 24, 14-20, doi:10.1002/hep.510240104 (1996).
Ayyavoo, V. et al. HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol 62, 93-99 (1997).
Mahalingam, S., Ayyavoo, V., Patel, M., Kieber-Emmons, T. & Weiner, D. B. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol 71, 6339-6347 (1997).
Kim, J. J. et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 28, 1089-1103, doi:10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L (1998)
MacGregor, R. R. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178, 92-100 (1998).
Kim, J. J. et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 102, 1112-1124, doi:10.1172/JCI3986 (1998).
Kim, J. J. et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 17, 3125-3135, doi:10.1038/sj.onc.1201736 (1998).
Jacotot, E. et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein rR and Bcl-2. J Exp Med 193, 509-519 (2001).
Jacotot, E. et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 191, 33-46 (2000).
Shostak, L. D. et al. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res 251, 156-165, doi:10.1006/excr.1999.4568 (1999).
Kim, J. J. et al. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. J Clin Invest 103, 869-877, doi:10.1172/JCI6024 (1999).
Toy, E. P., Rodriguez-Rodriguez, L., McCance, D., Ludlow, J. & Planelles, V. Induction of cell-cycle arrest in cervical cancer cells by the human immunodeficiency virus type 1 viral protein R. Obstet Gynecol 95, 141-146 (2000)
Ayyavoo, V. et al. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes. AIDS 14, 1-9 (2000).
Muthumani, K., Montaner, L. J., Ayyavoo, V. & Weiner, D. B. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1Vpr function in macrophages and T-cells. DNA Cell Biol 19, 179-188, doi:10.1089/104454900314564 (2000).
Kim, J. J. et al. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. J Virol 74, 3427-3429 (2000).
Yasuda, J., Miyao, T., Kamata, M., Aida, Y. & Iwakura, Y. T cell apoptosis causes peripheral T cell depletion in mice transgenic for the HIV-1 vpr gene. Virology 285, 181-192, doi:10.1006/viro.2001.0964 (2001).
Kim, J. J., Yang, J. S., Dang, K., Manson, K. H. & Weiner, D. B. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res 7, 882s-889s (2001)
Kim, J. J., Yang, J. S., Manson, K. H. & Weiner, D. B. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine 19, 2496-2505 (2001).
Kim, J. J. et al. Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization. Virology 285, 204-217, doi:10.1006/viro.2001.0958 (2001).
Kim, J. J. et al. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 20, 4497-4506, doi:10.1038/sj.onc.1204542 (2001).
Yang, J. S. et al. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis 184, 809-816, doi:10.1086/323395 (2001).
Ramanathan, M. P., Curley, E., 3rd, Su, M., Chambers, J. A. & Weiner, D. B. Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signaling. J Biol Chem 277, 47854-47860, doi:10.1074/jbc.M203905200 (2002).
Mirani, M. et al. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 169, 6361-6368 (2002).
Muthumani, K. et al. Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene 21, 4613-4625, doi:10.1038/sj.onc.1205549 (2002).
Muthumani, K. et al. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J Med Primatol 31, 179-185 (2002).
Muthumani, K., Hwang, D. S., Dayes, N. S., Kim, J. J. & Weiner, D. B. The HIV-1 accessory gene vpr can inhibit antigen-specific immune function. DNA Cell Biol 21, 689-695, doi:10.1089/104454902760330237 (2002).
Muthumani, K. et al. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 277, 37820-37831, doi:10.1074/jbc.M205313200 (2002).
Yang, J. S. et al. Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis 8, 1379-1384, doi:10.3201/eid0812.020224 (2002).
Muthumani, K., Choo, A. Y., Hwang, D. S., Ugen, K. E. & Weiner, D. B. HIV-1 Vpr: enhancing sensitivity of tumors to apoptosis. Curr Drug Deliv 1, 335-344 (2004)
Muthumani, K. et al. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 17, 103-116, doi:10.1093/intimm/dxh190 (2005).
Kutzler, M. A. et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175, 112-123 (2005).
Muthumani, K. et al. Human immunodeficiency virus type 1 (HIV-1) Vpr-regulated cell death: insights into mechanism. Cell Death Differ 12 Suppl 1, 962-970, doi:10.1038/sj.cdd.4401583 (2005).
Otero, M. et al. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine 24, 4461-4470, doi:10.1016/j.vaccine.2005.08.010 (2006).
Ramanathan, M. P. et al. Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology 345, 56-72, doi:10.1016/j.virol.2005.08.043 (2006).
Muthumani, K. et al. HIV-1 Viral protein-r (Vpr) protects against lethal superantigen challenge while maintaining homeostatic T cell levels in vivo. Mol Ther 12, 910-921, doi:10.1016/j.ymthe.2005.05.009 (2005)
Ramanathan, M. P. et al. Expression and evolutionary analysis of West Nile virus (Merion strain). J Neurovirol 11, 544-556, doi:10.1080/13550280500385229 (2005).
Draghia-Akli, R., Li, X. & Schwartz, R. J. Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector. Nat Biotechnol 15, 1285-1289, doi:10.1038/nbt1197-1285 (1997).
Khan, A. S. et al. Effects of plasmid-mediated growth hormone-releasing hormone supplementation on LL-2 adenocarcinoma in mice. Mol Ther 8, 459-466 (2003).
Khan, A. S. et al. Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice. Cancer Gene Ther 12, 54-60, doi:10.1038/sj.cgt.7700767 (2005).
Prud'homme, G. J., Glinka, Y., Khan, A. S. & Draghia-Akli, R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 6, 243-273 (2006).
Fiorotto, M. L., Lopez, R., Oliver, W. T., Khan, A. S. & Draghia-Akli, R. Transplacental transfer of a growth hormone-releasing hormone peptide from mother to fetus in the rat. DNA Cell Biol 25, 429-437, doi:10.1089/dna.2006.25.429 (2006).
Draghia-Akli, R. & Khan, A. S. Muscle and fat mass modulation in different clinical models. Methods Mol Biol 423, 449-460, doi:10.1007/978-1-59745-194-9_35 (2008).
Draghia-Akli, R. & Khan, A. S. In vivo electroporation of gene sequences for therapeutic and vaccination applications. Recent Pat DNA Gene Seq 1, 207-213 (2007).
Curcio, C. et al. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther 15, 108-114, doi:10.1038/sj.cgt.7701106 (2008).
Cristillo, A. D. et al. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 366, 29-35, doi:10.1016/j.bbrc.2007.11.052 (2008)
Laddy, D. J. et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 3, e2517, doi:10.1371/journal.pone.0002517 (2008).
Bodles-Brakhop, A. M. & Draghia-Akli, R. DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 7, 1085-1101, doi:10.1586/14760584.7.7.1085 (2008).
